Gainers & Losers Of The Day: BNTC, PULM, CALA, STML, CORI...

Stemline Therapeutics Inc. plunged over 42%, following a patient death in its ongoing pivotal phase II trial of SL-401 in blastic plasmacytoid dendritic cell neoplasm.

from RTT - Biotech http://ift.tt/2k76wq4
via IFTTT